Abstract
In order to help resolve the clinical significance of variants predicted to alter splicing patterns, and identify splice-altering variants in regions outside of the reportable range of routine hereditary cancer DNA sequencing tests, we initiated an IRB-approved RNA-sequencing research study at Invitae. The study was designed to address four distinct aims. First, we wanted to develop a robust and reliable approach for analyzing splicing changes in whole blood for a maximum number of genes included in Invitae's 84 gene Multi-Cancer panel.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
